Stefan Knapp studied chemistry at the University of Marburg, Marburg, Germany, and University of Illinois, Ill, USA. He obtained his Ph.D. degree in protein crystallography at the Karolinska Institute in Solna, Sweden (1996), and stayed at the Karolinska Institute also as a Postdoctoral Scientist (1996–1999). Prof. Knapp joined Pharmacia Corporation in 1999 as a Principal Research Scientist in structural biology and biophysics and left the company in 2004 after the acquisition of Pharmacia by Pfizer to build up a group at the Structural Genomics Consortium in Oxford (SGC). Since 2008 he works as a Professor at the Department of Clinical Medicine (NDM) at Oxford. His research interest is the rational design and development of selective inhibitors that target protein kinases as well as for protein interactions mediated by epigenetic reader domains such as bromodomains.
Biography Updated on 2 November 2012